Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,301 papers from all fields of science
Search
Sign In
Create Free Account
2-amino-1,3,4-butanetriol
Known as:
syn-2-amino-1,3,4-butanetriol
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Amino Alcohols
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
haracterization and multi-step transketolase-- transaminase ioconversions in an immobilized enzyme microreactor ( IEMR ) with acked tube
A. Halima
,
Nicolas Szitaa
,
Frank Baganza
2013
Corpus ID: 46986998
The concept of de novo metabolic engineering through novel synthetic pathways offers new directions for multi-step enzymatic…
Expand
2007
2007
One-pot synthesis of amino-alcohols using a de-novo transketolase and beta-alanine: pyruvate transaminase pathway in Escherichia coli.
C. U. Ingram
,
M. Bommer
,
+4 authors
G. Lye
Biotechnology and Bioengineering
2007
Corpus ID: 45772444
Biocatalysis continues to emerge as a powerful technique for the efficient synthesis of optically pure pharmaceuticals that are…
Expand
2001
2001
Orthogonally protected, enantiopure syn-2-amino-1,3,4-butanetriol: a general building block for syn-amino alcohols.
S. Kwon
,
S. Ko
Journal of Organic Chemistry
2001
Corpus ID: 40558994
2000
2000
(1S)-1-[(4R)-2,2-dimethyl-1,3-dioxolan+-4-yl][-2-hydroxyethylamm onium benzoate, a versatile building block for chiral 2-aminoalkanols: concise synthesis and application to nelfinavir, a potent HIV…
Takashi Inaba
,
Yasuki Yamada
,
Hiroyuki Abe
,
Shoichi Sagawa
,
Hidetsura Cho
Journal of Organic Chemistry
2000
Corpus ID: 24665911
A concise synthesis of a versatile chiral C4 building block for 2-aminoalkanols, (1S)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE